Kiora Pharmaceuticals (NASDAQ:KPRX) released its fourth-quarter and full-year 2025 financial results on Wednesday, detailing a streamlined balance sheet and steady clinical momentum for its pipeline of retinal disease treatments.
The company concluded the fiscal year with approximately $17.1 million in cash and cash equivalents, supplemented by $3.5 million in receivables.
Management stated that this capital position, bolstered by a disciplined spending approach, provides a financial runway extending into late 2027.
For the full year 2025, Kiora reported a net loss of $10.8 million, as the firm continues to prioritize research and development over commercial infrastructure.
The financial stability is further supported by an ongoing strategic partnership with Senju Pharmaceutical.
The option agreement between the two firms could potentially provide Kiora with up to $110 million in total deal value, providing a non-dilutive funding pathway as its candidates progress through the clinic.
On the operational front, Kiora is currently advancing two key Phase 2 clinical programs.
The ABACUS-2 trial is evaluating KIO-301, a small molecule "photoswitch" designed to restore vision in patients with late-stage retinitis pigmentosa.
Simultaneously, the KLARITY trial is testing KIO-104, a next-generation anti-inflammatory for the treatment of posterior non-infectious uveitis.
The company expects to reach significant clinical milestones in the coming year, with initial readouts for both programs anticipated in 2027.